Sterling Pharma to acquire CiVentiChem in the US

9 Apr 2019

The acquisition will enhance the CDMO's chemistry development capabilities to support pre-clinical and early phase clinical supply.

UK-based CDMO, Sterling Pharma Solutions, has announced its acquisition of CiVentiChem’s US facility located in Cary, North Carolina, US.

Sterling Pharma to acquire CiVentiChem in the US

The new facility, located close to the Research Triangle Park, will allow Sterling to offer a local presence to its US clients and enhance its chemistry development capabilities to support pre-clinical and early phase clinical supply.

The acquisition follows Sterling’s record growth, with the company more than doubling its sales since its formation in 2016 following a management buy-out (MBO). With the support of its new investor, GHO Capital, the acquisition advances Sterling’s strategy to build a global chemistry services business.

Commenting on the announcement, Kevin Cook, CEO of Sterling Pharma Solutions, said: “We’re delighted to announce our acquisition of CiVentiChem in the US. We’ve been keen to expand our presence in the US market and the site’s capabilities complement our current service offering.

“The North American market now makes up 70% of our customer portfolio which was one of the major reasons behind the decision to look for a facility in the US. This has been primarily driven by the market’s emerging pharma sector and customer demand for our specialist capabilities in complex and challenging chemistry.”

The acquisition of CiVentiChem US is the latest step in Sterling Pharma Solutions’ ongoing growth strategy to allow it to continue providing high service levels to its global customer base.

The purchase of the new facility follows the completion of a majority acquisition of Sterling Pharma Solutions by the specialist European healthcare investor, GHO Capital earlier this year.

Sterling Pharma Solutions is the UK’s largest provider of small molecule API development and manufacturing services to the pharmaceutical industry, specialising in handling challenging chemistries. With over 50 years’ experience, the team can manage the most complex API and API intermediate challenges and its facilities have the scale to go from proof-of-concept to commercial manufacture.

CiVentiChem is a leading provider of solutions for complex chemistry problems across the pharmaceutical, biotech and life sciences industry. Founded by Dr. Bhaskar Venepalli and Dr. Srinivas Chittineni, CiVentiChem’s US facility houses development laboratories and kilo scale cGMP suites.

“We have developed excellent relationships with many clients and this acquisition will make Sterling a global player in CDMO business” said Bhaskar Venepalli, CiVentiChem President and CEO. CiVentiChem will continue to operate out of its own facility in India as a separate entity to Sterling.


Read More

Related news

Isotype-specific secondary antibodies for improved signal detection

Isotype-specific secondary antibodies for improved signal detection

10 Apr 2019

Offer an alternative to cross-adsorbed secondary antibodies when absolute specificity is required.

Read more 
Catalent expands OptiMelt hot melt extrusion capabilities

Catalent expands OptiMelt hot melt extrusion capabilities

4 Apr 2019

The investment includes the addition of equipment to enhance development capabilities for preclinical and early clinical phase development, as well as adding downstream processing technologies to support HME formulations.

Read more 
'Drugs from bugs' joint venture

'Drugs from bugs' joint venture

4 Apr 2019

Lonza and Chr. Hansen create a strategic joint venture to become the partner of choice for developing and manufacturing live biotherapeutic products for pharma and biotech customers.

Read more 
Curcumin and pomegrantes - new hope for Alzheimer’s prevention?

Curcumin and pomegrantes - new hope for Alzheimer’s prevention?

3 Apr 2019

New research at University of Warwick will test how curcumin kick-starts the brain’s cleansing of damaging plaques and cells.

Read more 
MedPharm's appointment with Destiny

MedPharm's appointment with Destiny

28 Mar 2019

Global contract provider to develop new XF-platform drug formulations for the treatment of a number of topically treated infections, including diabetic foot ulcers and ophthalmic infections.

Read more 
Third Sartorius Research Xchange Forum 2019 focuses on CAR-T cell therapy

Third Sartorius Research Xchange Forum 2019 focuses on CAR-T cell therapy

13 Mar 2019

Event for experts from academia and industry, including talks, live demo sessions, and panel discussion.

Read more 
Envigo launches PATHWAY to enable FIH clinical trials

Envigo launches PATHWAY to enable FIH clinical trials

11 Mar 2019

PATHWAY manages the complexity of the entire safety assessment process on behalf of the company’s pharmaceutical and biotechnology customers.

Read more 
Biogen acquisition boosts its ophthalmology pipeline

Biogen acquisition boosts its ophthalmology pipeline

4 Mar 2019

Nightstar Therapeutics has two potentially first-in-class mid- to late-stage clinical assets as well as preclinical programs.

Read more 
Uniqsis expands LED photoreactor range

Uniqsis expands LED photoreactor range

3 Mar 2019

The availability of three new alternative switchable LED configurations provides chemists with the unique ability to optimally undertake almost any photochemistry reaction.

Read more 
Crowdfund and discover promising therapeutics via Molecule

Crowdfund and discover promising therapeutics via Molecule

21 Feb 2019

Connecting scientists, patients, and industry to advance drug development in a collaborative open market.

Read more